Scarica l'app Stockscreener
14.54
3.41%
0.48
Dopo l'orario di chiusura:
14.54
Precedente Chiudi:
$14.06
Aprire:
$14.15
Volume 24 ore:
68,226
Relative Volume:
0.31
Capitalizzazione di mercato:
$544.39M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-1.76%
1M Prestazione:
+33.39%
6M Prestazione:
+16.60%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$14.09
$14.62
Intervallo di 1 settimana:
$13.43
$15.70
Portata 52W:
$5.485
$31.13
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Nome
Oruka Therapeutics Inc
Settore
Industria
Telefono
650-606-7910
Indirizzo
855 OAK GROVE AVE., MENLO PARK
Confronta ORKA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
14.54 | 526.41M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-22 | Iniziato | BTIG Research | Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2024-10-11 | Iniziato | Stifel | Buy |
| 2024-10-07 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-17 | Iniziato | Leerink Partners | Outperform |
| 2024-09-16 | Iniziato | TD Cowen | Buy |
| 2024-09-13 | Iniziato | Jefferies | Buy |
| 2018-02-27 | Iniziato | Ascendiant Capital Markets | Buy |
| 2013-10-09 | Iniziato | Dawson James | Buy |
Mostra tutto
Oruka Therapeutics Inc Borsa (ORKA) Ultime notizie
What drives Oruka Therapeutics Inc. stock priceOverwhelming financial success - Autocar Professional
Is Oruka Therapeutics Inc. a good long term investmentAccelerated investment success - Autocar Professional
H.C. Wainwright reiterates Buy rating on Oruka Therapeutics stock as FDA clears IND - Investing.com Canada
Oruka Therapeutics Shares Climb After FDA Greenlights Psoriasis Drug Trial - MSN
Oruka Therapeutics Inc. Stock Analysis and ForecastMassive profits - Autocar Professional
What analysts say about Oruka Therapeutics Inc. stockExponential return rates - jammulinksnews.com
Wedbush Reiterates Outperform Rating for Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Oruka Therapeutics Announces IND Clearance for EVERLAST-A - GlobeNewswire
Oruka Therapeutics stock rises after FDA clears IND for psoriasis drug - Investing.com India
Stifel reiterates Buy rating on Oruka Therapeutics stock with $47 target - Investing.com Canada
Oruka Therapeutics: Revolutionizing Psoriasis Treatment with Extended-Dosing Biologics - AInvest
FDA clears Oruka’s IND for psoriasis drug ORKA-001 phase 2a trial - Investing.com India
Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September - Yahoo Finance
How high can Oruka Therapeutics Inc. stock price go in 2025Balanced Risk Reward Portfolio - Newser
How Oruka Therapeutics Inc. stock performs during market volatilityDaily Volume Leaders - Newser
Why Oruka Therapeutics Inc. stock attracts strong analyst attentionFree Real-Time Stock Data - Newser
What makes Oruka Therapeutics Inc. stock price move sharplyWeekly Big Movers - Newser
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Rating of “Buy” from Analysts - Defense World
Oruka Therapeutics announces COO appointment - MSN
Oruka Therapeutics Shares Soar 16.1% on Executive Promotion, Index Inclusion - AInvest
Oruka Therapeutics Promotes Laura Sandler to COO - MarketScreener
Oruka Therapeutics promotes Laura Sandler to chief operating officer - Investing.com
Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer - GlobeNewswire
Oruka Therapeutics Appoints New Chief Operating Officer - TipRanks
Oruka Therapeutics, Inc.(NasdaqGM: ORKA) added to Russell 3000E Index - MarketScreener
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Recommendation of “Buy” by Analysts - Defense World
Wall Street Zen Downgrades Oruka Therapeutics (NASDAQ:ORKA) to Sell - Defense World
Millennium Management LLC Makes New Investment in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
Oruka Therapeutics Inc Azioni (ORKA) Dati Finanziari
Non sono disponibili dati finanziari per Oruka Therapeutics Inc (ORKA). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
4.91%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):